Organigram Global (OGI) Cost of Revenue (2018 - 2026)
Organigram Global (OGI) posted quarterly Cost of Revenue of $61.9 million for Q1 2026, up 93.72% year-on-year from $31.9 million in Q1 2025, and up 27.78% on a QoQ basis from $48.4 million in Q4 2025.
Organigram Global (OGI) Cost of Revenue (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Cost of Revenue for 7 consecutive years, with $61.9 million the latest figure, recorded in Q1 2026.
- Quarterly Cost of Revenue rose 93.72% year-over-year to $61.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $162.7 million (down 11.8% YoY) and the FY2025 annual result came in at $133.6 million, changed N/A from the prior year.
- Cost of Revenue climbed to $61.9 million in Q1 2026 per OGI's latest filing, from $48.4 million in the prior quarter.
- Over the last five years, Cost of Revenue for OGI reached as high as $61.9 million in Q1 2026 and fell as low as $20.5 million in Q4 2024.
- A 3-year average of $40.7 million and a median of $40.2 million in 2025 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2025 — Cost of Revenue jumped 136.3% — and 2026, when it jumped 93.72%.
- Year by year, Cost of Revenue stood at $20.5 million in 2024, then surged by 136.3% to $48.4 million in 2025, then gained by 27.78% to $61.9 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $61.9 million, $48.4 million, and $31.9 million for Q1 2026, Q4 2025, and Q1 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Organigram Global | 121.15 Mn | 154.23 Mn | 28.97 Mn | 61.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61.85 Mn |
| Mar 31, 2026 | 61.85 Mn |
| Dec 31, 2025 | 48.40 Mn |
| Dec 31, 2025 | 48.40 Mn |
| Mar 31, 2025 | 31.93 Mn |
| Mar 31, 2025 | 31.93 Mn |
| Dec 31, 2024 | 20.48 Mn |
| Dec 31, 2024 | 20.48 Mn |
| May 31, 2021 | 77.70 Mn |
| May 31, 2021 | 77.70 Mn |
| Feb 28, 2021 | 54.32 Mn |
| Feb 28, 2021 | 54.32 Mn |
| Nov 30, 2020 | 23.17 Mn |
| Nov 30, 2020 | 23.17 Mn |
| Aug 31, 2020 | 21.59 Mn |
| Aug 31, 2020 | 21.59 Mn |
| May 31, 2020 | 31.73 Mn |
| May 31, 2020 | 31.73 Mn |
| Feb 29, 2020 | 15.81 Mn |
| Feb 29, 2020 | 15.81 Mn |